iCAD (NASDAQ:ICAD) Share Price Passes Above 200-Day Moving Average – Time to Sell?

iCAD, Inc. (NASDAQ:ICAD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.61 and traded as high as $2.06. iCAD shares last traded at $1.96, with a volume of 197,827 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.

iCAD Trading Down 4.9 %

The stock has a fifty day moving average of $1.83 and a two-hundred day moving average of $1.61. The company has a market capitalization of $52.02 million, a PE ratio of -15.08 and a beta of 1.40.

Institutional Inflows and Outflows

An institutional investor recently raised its position in iCAD stock. Perritt Capital Management Inc increased its holdings in iCAD, Inc. (NASDAQ:ICAD) by 14.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 159,900 shares of the technology company’s stock after purchasing an additional 19,917 shares during the quarter. Perritt Capital Management Inc owned 0.60% of iCAD worth $208,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.